Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
During the visit, Medicilon's R&D Team introduced their one-stop preclinical services platform for pharmaceutical R&D. They highlighted the Medicilon's capabilities and technical strengths in safety evaluation, pharmacology, and pharmacokinetics, with special attention to PROTAC, ADC, nucleic acids, bispecific antibodies, peptides, vaccines, and CGT. BOSTON, July 31, 2024 /PRNewswire/ -- Recently, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement. The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly ADCs, small nucleic acids, and CGT (cell and gene therapy) drugs. The goal of this partnership is to advance the innovation of the Chinese pharmaceutical industry to compete on an international level.
最近，上海美兰生物医药科技有限公司（“美兰生物”）和恒瑞医药股份有限公司（“恒瑞医药”）签署了战略合作协议。合作方将重点关注新药模式的临床前评估，特别是ADC、小分子核酸和CGt（细胞基因治疗）药物。此次合作的目标是推进中国药业板块的创新，以在全球范围内展开竞争。
The elevated commitment to collaboration between Medicilon and Hengrui Pharma builds upon the solid foundation from years of experience and well-established trust. The organizations plan to integrate Medicilon's preclinical R&D expertise with Hengrui Pharma's innovative strategies and market influence. Medicilon will leverage its technological advantages in drug discovery and development to provide Hengrui Pharma with a range of preclinical services, focusing on efficacy testing, pharmacokinetics, and toxicology studies for new drug modalities. Medicilon and Hengrui Pharma will combine efforts to generate breakthroughs in pharmaceutical therapies.
美兰生物和恒瑞医药加强合作的承诺建立在多年的经验和良好信任的坚实基础之上。合作双方计划将美兰生物的临床前研发专业知识与恒瑞医药的创新战略和市场影响结合起来。美兰生物将利用其在药物发现和开发方面的技术优势，为恒瑞医药提供一系列临床前服务，重点是新药模式的疗效测试、药代动力学和毒理学研究。美兰生物和恒瑞医药将共同努力实现制药疗法的突破。
The atmosphere of the exchange was enthusiastic and congenial. Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang, along with other executives, visited Medicilon's Pudong Chuansha Park. They were welcomed by Medicilon's CEO Chunlin Chen and key team members.
交流气氛热烈友好。恒瑞医药副总经理兼全球研发总裁张连山先生与其他高管一同访问了美兰生物的浦东川沙园区。他们受到了美兰生物CEO陈春林博士和重要团队成员的热情欢迎。
During the visit, Medicilon's R&D Team introduced their one-stop preclinical services platform for pharmaceutical R&D. They highlighted the Medicilon's capabilities and technical strengths in safety evaluation, pharmacology, and pharmacokinetics, with special attention to PROTAC, ADC, nucleic acids, bispecific antibodies, peptides, vaccines, and CGT.
在访问期间，美兰生物的研发团队介绍了其一站式药物研发临床前平台，强调了药物安全评价、药理学和药代动力学等方面的核心技术和实力，特别关注了PROTAC、ADC、核酸、双特异性抗体、肽类、疫苗和CGt。
Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang stated, "Medicilon possesses robust innovation capabilities and service quality in this field, making it a trusted CRO partner. The collaboration between Hengrui Pharma and Medicilon not only acknowledges past achievements but also represents a deep exploration of future collaboration potential and forward-looking strategic planning."
恒瑞医药副总经理兼全球研发总裁张连山表示：“美兰生物在这个领域拥有弹性创新和服务品质，是值得信赖的CRO合作伙伴。恒瑞医药与美兰生物之间的合作不仅承认了过去的成就，更代表了未来合作潜力和前瞻性战略规划的深入探讨。”
Medicilon's Founder & CEO Chunlin Chen stated, "Medicilon and Hengrui Pharma firmly believe that, through close collaboration, the process of drug R&D will be accelerated in the future, contributing to the innovative development of the global pharmaceutical industry."
美兰生物创始人兼CEO陈春林表示：“美兰生物和恒瑞医药坚信，通过密切合作，未来的药物研发过程将得到加速，从而促进全球制药行业的创新发展。”
Website:
网址：
SOURCE Medicilon Inc.
来源：美兰生物
